RNA Diagnostics Inc. is developing molecular diagnostic tools to radically improve the management of breast cancer treatment
Clinical Trial Underway
Patient accrual is progressing well in the RDA™ Clinical Trial at Sunnybrook Hospital, Toronto. Fifty patients with biopsy proven unresected breast cancer eligible for neoadjuvant chemotherapy are expected to participate in the study. The primary goal of the Sunnybrook trial is to determine the optimal time to perform the Tumor RNA Disruption Assay (RDA™). Secondary objectives are: (1) to refine cut-off points between responders, non-responders and partial responders to chemotherapy during neoadjuvant treatment and (2) to standardize biopsy accession, stabilization, shipping and storage.
New Trial Planned for Teaching Hospital Network, McGill University, Montreal, Quebec
Dr. Jean Francois Boileau, a breast cancer surgeon, formerly at Sunnybrook Hospital and recently moved to the Jewish General Hospital in Montreal, has initiated a new RDA™ clinical trial at the Teaching Hospital Network of McGill University. This trial is expected to begin accrual of patients in December 2013. Dr. Boileau and his colleagues in Quebec are strong advocates of neoadjuvant therapy as a way to improve treatment for breast cancer patients.
The first version of the RNA Disruption Assay (RDA™) system has been completed and is being applied in the Sunnybrook Trial.
The Rna Diagnostics research and development laboratory at Sudbury continues to explore RDA™ in a range of in vivo and in vitro models to expand the utility of the technology.
Clinical Research Collaboration with Instituti Ospitaliere di Cremona
A high value research collaboration has been established with a leading centre for breast cancer research at the Instituti Ospitalieri di Cremona, in Northern Italy. The Breast Group at the Cremona Hospital is devoted to the improvement of breast cancer patient lives through neoadjuvant treatments. The interdisciplinary Breast Group team under the leadership of Dr Alberto Bottinni,and Dr. Daniele Generali operate a molecular medicine laboratory within the breast clinic. The Cremona Group is very excited about the potential of RDA™ to assist in the treatment of their patients. Rna Diagnostics is working with the Cremona Group on several human clinical studies involving the assessment of treatment in neoadjuvant settings.
Tumor samples from Cremona are now being analyzed at the Rna Diagnostics laboratory in Sudbury, Ontario.
Photo: Laura Pritzker, Rna Diagnostics Principal Scientist and John Connolly, VP Corporate Development load material for RDA Sunnybrook Clinical Trial
Rna Diagnostics nominated for Rising Star Award
San Antonio Breast Cancer Symposium
San Antonio Texas
Rna Diagnostics will present an abstract at this international symposium